Clinical Trial Update: Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a novel CAR T-cell therapy produced using a new technology for relapsed or refractory B-cell lymphoma is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• CAR T-cell therapy (new technology)

Snippet

Sponsor: Instituto de Investigación Biomédica de Salamanca | Conditions: Refractory B-Cell Lymphoma, B-cell Lymphoma Recurrent | Phase 1, Phase 2 | Status: RECRUITING